Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Capecitabine Formulations in Cancer Patients
NCT04420871Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Dec 2018
- Primary completion
- Dec 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of capecitabine in colorectal cancer (CRC) and breast cancer, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Peak Plasma Concentration at 18 days, Area under the plasma concentration versus time curve from time 0 to last measurable concentration at 18 days and 1 more. Started Dec 2018; status: completed.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)breast cancer
Beyond the preview
Go deeper on NCT04420871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04420871.